REG - Alkemy Capital Invs. - Grant of Options

Alkemy Capital InvestmentsAnnouncement

04/08/2022 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220804:nRSD8525Ua&default-theme=true

RNS Number : 8525U  Alkemy Capital Investments PLC  04 August 2022

 

4 August 2022

 

Alkemy Capital Investments Plc

Grant of Options

 

Alkemy Capital Investments plc ("Alkemy") (LSE: ALK) is pleased to announce
that further to its announcement earlier today it has granted 590,000 share
options at £1 per share, for a period of 5 years, to further align Directors
and senior management with shareholders.

The share options will vest one-third immediately, one-third following
completion of construction finance for train 1 of TVL's processing facility in
Teesside, and one-third following commissioning of train 1 of TVL's processing
facility.

In addition the share options will only be exerciseable if the share price of
the Company is in excess of £5 per share for 10 consecutive days.

The grant of share options to directors is set out below:

                           Options  Exercise  Price   Term
 Paul Atherley (Chairman)  175,000  £1.00             5 years
 Sam Quinn (Director)      140,000  £1.00             5 years
 Helen Pein (Director)     75,000   £1.00             5 years

 

Further information

For further information, please visit the Company's website:
www.alkemycapital.co.uk (http://www.alkemycapital.co.uk) or
www.teesvalleylithium.co.uk (http://www.teesvalleylithium.co.uk)

-Ends-

 Alkemy Capital Investments Plc    Tel: 0207 317 0636

 Sam Quinn                         info@alkemycapital.co.uk (mailto:info@alkemycapital.co.uk)
 Buchanan                          Tel: 0207 466 5000

 Bobby Morse/Abigail Gilchrist     TVL@buchanan.uk.com
 VSA Capital Limited               Tel: 0203 005 5000

 Andrew Monk (corporate broking)   amonk@vsacapital.com (mailto:amonk@vsacapital.com)

 Andrew Raca (corporate finance)   araca@vsacapital.com (mailto:araca@vsacapital.com)
 Shard Capital Partners LLP

 Damon Heath                       Tel: 0207 186 9952

                                   damon.heath@shardcapital.com (mailto:damon.heath@shardcapital.com)

 Isabella Pierre                   Tel: 0207 186 9927

                                   isabella.pierre@shardcapital.com (mailto:isabella.pierre@shardcapital.com)

 

NOTES TO EDITORS

Alkemy is seeking to develop, construct and operate the world's leading
independent and sustainable lithium hydroxide production facility.

Alkemy, through its wholly-owned subsidiary Tees Valley Lithium, has secured
exclusivity to negotiate an option to lease over a 9.6ha brownfields site at
the Wilton International Chemicals Park located in Teesside, a major UK
Freeport.

Alkemy has completed a Class 4 Feasibility Study for its proposed lithium
hydroxide facility to process feedstock imported from various sources to
produce 96,000 tonnes of premium, low-carbon lithium hydroxide annually,
representing around 15% of Europe's projected demand.

 

 

Forward Looking Statements

This news release contains forward‐looking information. The statements are
based on reasonable assumptions and expectations of management and Alkemy
provides no assurance that actual events will meet management's expectations.
In certain cases, forward‐looking information may be identified by such
terms as "anticipates", "believes", "could", "estimates", "expects", "may",
"shall", "will", or "would". Although Alkemy believes the expectations
expressed in such forward‐looking statements are based on reasonable
assumptions, such statements are not guarantees of future performance and
actual results or developments may differ materially from those projected. In
addition, factors that could cause actual events to differ materially from the
forward-looking information stated herein include any factors which affect
decisions as to how to develop the project, process the materials and exercise
the options in respect of the lease, which may include changes in market
conditions, changes in metal prices, general economic and political
conditions, environmental risks, and community and non-governmental actions.
Such factors will also affect whether Alkemy will ultimately receive the
benefits anticipated pursuant to relevant agreements. This list is not
exhaustive of the factors that may affect any of the forward‐looking
statements. These and other factors should be considered carefully and readers
should not place undue reliance on forward-looking information.

 

The Notification of Dealing Form provided in accordance with the requirements
of the Market Abuse Regulation in relation to the transaction listed above is
set out below.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1.     Paul Atherley

                                                                   2.     Sam Quinn

                                                                   3.     Helen Pein

 2    Reason for the notification

 a)   Position/status                                              1.     Chairman

                                                                   2.     Director

                                                                   3.     Director

 b)   Initial notification /Amendment                              Intial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Alkemy Capital Investments PLC

 b)   LEI                                                          213800NW5GVIRMXSRL48

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares

      Identification code                                          GB00BMD6C023

 b)   Nature of the transaction                                    Grant of  Share Options subject to vesting conditions and only be

                                                            exerciseable if the share price of the Company's ordinary shares is in excess
                                                                   of £5 per share for 10 consecutive days.
 c)   Price(s) and volume(s)

                                                                                         Excersie Price(s)     Volume(s)
                                                                                         1.     1.00           175,000

                                                                                         2.     1.00           140,000

                                                                                         3.     1.00           75,000

 d)   Aggregated information

      - Aggregated volume                                          N/A

      - Price                                                      £1.00

 e)   Date of the transaction                                      03/08/2022

 f)   Place of the transaction                                     Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBCGDIDUGDGDX